Publications by authors named "A M Cingolani"

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, responsible for Coronavirus Disease 2019 (COVID-19), exhibits a spectrum of clinical manifestations, ranging from asymptomatic to severe pulmonary dysfunction or death. The variability in COVID-19 severity has largely been attributed to the host's genetic characteristics, suggesting a polygenic genetic architecture, without significant strong evidence of sex-related genetic differences. In this Italian retrospective case-control study, we investigated the association between COVID-19 severity (severe vs.

View Article and Find Full Text PDF

Objectives: To unravel the still unexplored HBV-replicative kinetics in anti-HBc-positive/HBsAg-negative people-with-HIV (PWH) suspending tenofovir disoproxil-fumarate/tenofovir-alafenamide (TDF/TAF).

Methods: A total of 101 anti-HBc-positive/HBsAg-negative PWH switching to TDF/TAF-sparing therapy were included. Serum HBV-DNA and HBV-RNA were quantified by droplet-digital-PCR at switching (T0), within 12 months (T1) and 12-24 months postswitch (T2).

View Article and Find Full Text PDF

Perfluoroalkyl substances (PFASs) are a large class of persistent emerging pollutants, ubiquitous in different environmental compartments. In this study, twenty-one PFASs were determined in seventy-eight water samples collected from six different rivers in the Umbria region (central Italy) during a 13-month monitoring campaign. The sum of the twenty-one target analytes (ΣPFASs) ranged from 2.

View Article and Find Full Text PDF

Background: Implementation level of long-acting injectable agents cabotegravir/rilpivirine (LAI CAB/RPV) for human immunodeficiency virus (HIV) treatment in Italy is still not known. The aim of this study is to identify the status of implementation of LAI CAB-RPV and its barriers.

Materials And Methods: A cross-sectional online survey was conducted among infectious diseases (ID) physicians and nurses belonging to the ICONA network in Italy.

View Article and Find Full Text PDF
Article Synopsis
  • The study focused on the effectiveness of tixagevimab/cilgavimab (T/C) as pre-exposure prophylaxis (PrEP) in immunocompromised individuals, categorizing them into groups based on their COVID-19 history.
  • A total of 231 participants were included, with a significant portion having hematological diseases and receiving multiple vaccine doses; breakthrough infections (BTIs) occurred in 56 participants (24%) but were mostly mild to moderate.
  • Immune markers were measured over time, showing an initial increase in anti-RBD IgG antibodies at 3 months, a decline at 6 months, and low neutralizing antibodies, reinforcing T/C's clinical efficacy in reducing severe COVID-19
View Article and Find Full Text PDF